Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 67.43 +1.26 (1.91%)
price chart
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B  FierceBiotech
Bristol Will Buy Diabetes Drug Maker  Wall Street Journal
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS� (apixaban) for the ...
FDA Once Again Delays Approval Of Apixaban (Eliquis)  Forbes
FDA Unexpectedly Delays Move on Anticlotting Drug  New York Times
Terminally ill patients should have access to last-chance therapies
But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...
Bristol-Myers Immune Drug Puts Deadly Cancers on Hold in Study
June 4 (Bloomberg) -- The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Loneliness Linked To Premature Death
In Monday's online issue of the Archives of Internal Medicine, Dr. Jacob Udell of Brigham and Women's Hospital and Harvard Medical School in Boston and his co-authors said living alone was associated with four-year mortality (14.1 per cent vs. 11.1 per ...